source
- Neurosterix secures $105M Series B to launch phase 2 schizophrenia trialAddex Therapeutics' spinout Neurosterix announced a $105 million Series B financing to fund its upcoming phase 2 trial of NTX-253 for schizophrenia. The round was led by a syndicate of leading lif…
- Game Changer Products recalls 10 Day Forecast capsules after FDA finds undeclared sildenafil and acetaminophenGame Changer Products LLC announced a voluntary nationwide recall of its 10 Day Forecast capsules, a dietary supplement marketed at 3200 mg. The FDA’s analysis detected the presence of undeclared…